Medtronic has bulked up its aortic portfolio with the $110m acquisition of Aptus Endosystems, a California company specializing in endovascular aneurysm repair and thoracic endovascular aneurysm repair. Aptus’ Heli-FX and Heli-FX Thoracic EndoAnchor systems feature an endovascular deployed anchor designed to attach a variety of aortic endografts to the native vessel wall, without the need for complicated procedures. The devices are CE marked and US FDA-cleared, and can be used with commercially available stent graft systems, including Medtronic’s Endurant and Valiant stent graft systems. Medtronic said it plans to pursue approval for <10mm infrarenal="" proximal="" neck="" indication="" for="" endurant="" with="" the="" use="" of="" the="" heli-fx="" endoanchor="">
The Aptus acquisition was the second M&A deal Medtronic had announced within the same day. On 19 June, the company also said it had acquired CardioInsight Technologies, a noninvasive...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?